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Meningococcal vaccinesGlycoconjugate vaccines are made of carbohydrate antigens covalently bound to a carrier protein to
enhance their immunogenicity. Among the different carrier proteins tested in preclinical and clinical
studies, five have been used so far for licensed vaccines: Diphtheria and Tetanus toxoids, the non-toxic
mutant of diphtheria toxin CRM197, the outer membrane protein complex of Neisseria meningitidis ser-
ogroup B and the Protein D derived from non-typeable Haemophilus influenzae. Availability of novel car-
riers might help to overcome immune interference in multi-valent vaccines containing several
polysaccharide-conjugate antigens, and also to develop vaccines which target both protein as well sac-
charide epitopes of the same pathogen. Accordingly we have conducted a study to identify new potential
carrier proteins. Twenty-eight proteins, derived from different bacteria, were conjugated to the model
polysaccharide Laminarin and tested in mice for their ability in inducing antibodies against the carbohy-
drate antigen and eight of them were subsequently tested as carrier for serogroup meningococcal C
oligosaccharides. Four out of these eight were able to elicit in mice satisfactory anti meningococcal ser-
ogroup C titers. Based on immunological evaluation, the Streptococcus pneumoniae protein spr96/2021
was successfully evaluated as carrier for serogroups A, C, W, Y and X meningococcal capsular saccharides.
 2016 GSK. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Glycoconjugate vaccines are safe and efficacious tools to pre-
vent infection and mortality against different encapsulated bacte-
rial pathogens [1–3].
In these type of vaccines carbohydrate antigens are covalently
bound to a carrier protein which provides T-cell epitopes that con-
fer a T dependent character to the saccharide moiety.
Five carrier proteins are currently included in licensed glyco-
conjugate vaccines [4–7]. Diphtheria (DT) and Tetanus toxoids
(TT), derived from the respective toxins after chemical detoxifica-
tion with formaldehyde, were initially selected as carriers because
of the safety track record accumulated with tetanus and diphtheria
vaccination [8]. CRM197, a non-toxic mutant of diphtheria toxin [9],
has been extensively used as carrier for licensed conjugate vacci-
nes against Haemophilus influenzae type b (Hib), Streptococcus
pneumoniae, Neisseria meningitidis) and for other vaccines in clini-
cal development. The outer membrane protein complex (OMPC)
of N. meningitidis serogroup B has been used as carrier for the
Hib conjugate vaccine developed by Merck [10]. Protein D, derivedfrom non-typeable H. influenzae (NTHi), has been used as carrier for
most of the polysaccharides included by GSK into the multivalent
pneumococcal conjugate vaccine recently licensed [11,12].
Multivalent conjugates administration and vaccines co-
administration can be associated with immune interference such
as carrier-specific enhancement of T-cell help, carrier-induced-
epitopic suppression (CIES) or bystander interference. Carrier
priming and suppression effect were investigated in both animal
and human studies and different behaviors between the commonly
used carriers were reported [13–15]. Considering these aspects,
novel carriers might help in avoiding or reducing the impact of
the above mentioned issues and enable the further development
of pediatric schedules and combinations [16].
Other proteins are increasingly used as carrier and some of
them have also been tested in clinical trials. The recombinant
non-toxic form of Pseudomonas aeruginosa exotoxin A (rEPA) has
been used as carrier for Shigella O-antigens [17] and Staphylococcus
aureus type 5 and 8 capsular polysaccahrides as well as for Sal-
monella Typhi Vi antigen [18–20]. rEPA is also used as a carrier
for glycoconjugate vaccines directly synthesized in Escherichia coli
against Shigella dysenteriae type 1 [21]. A rationally designed
recombinant protein containing strings of promiscuous human
CD4+ T-cell epitopes derived from various pathogens including
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virus, proved to be a very good carrier for Hib and meningococcal
oligosaccharides [22–24]. Endeavors to develop carrier proteins
which might also provide protection against a target pathogen,
have recently broadened to include candidates from diverse vac-
cine categories [25–30].
Taking advantage from the availability of several recombinant
proteins originated from a variety of reverse vaccinology projects
undertaken in our Research Center, we have conducted a study
to identify new carrier proteins, derived from different bacteria like
extraintestinal pathogenic E. coli (ExPEC), N. meningitidis serogroup
B (Men B), group A Streptococcus (GAS), group B Streptococcus (GBS)
and S. pneumoniae (sp).
The strategy was based on two steps: (a) immunogenicity
screening in mice of several recombinant proteins conjugated to
a model saccharide in comparison to CRM197 as benchmark carrier
protein; (b) testing selected carriers conjugated to meningococcal
carbohydrate antigens. Here we describe the results of this study.
Laminarin (Lam) was the model saccharide used for the first
immunogenicity screening, a neutral sugar antigen studied as vac-
cine candidate against infections induced by Candida albicans [31].2. Materials and methods
2.1. Reagents
Laminarin was obtained from Sigma Aldrich (L9634).
Serogroup A, C, W, Y meningococcal oligosaccharides were pro-
vided by the Manufacturing Department (GSK, Siena, Italy).
Men X polysaccharide was produced internally by Research
Center (GSK, Siena, Italy).
CRM197 was provided by the Manufacturing Department (GSK,
Siena, Italy).
Proteins tested as new carrier candidates were produced inter-
nally by Research Center (GSK, Siena, Italy).
Men B 961c (NadA or GNA1994), GNA2132-1030 (NHBA-
GNA1030) and GNA2091-fHbp (GNA2091–GNA1870) proteins
were provided by the Manufacturing Department (GSK, Siena,
Italy).
2.2. Preparation of protein carriers
The twenty eight recombinant proteins tested as potential new
carrier candidates were expressed in E. coli, twenty five of them
were expressed as His-tag fusion proteins and purified by immobi-
lized metal affinity chromatography. Details of cloning, expression
and purification strategy are reported in SI. All the proteins tested
are reported in Table 1 SI with bacteria origin, protein name and
alternative name reported in the bracket. Sp proteins were identi-
fied as spr when derived from R6 genome or D39 (spr1418 and
spr1712), non spr are derived from TIGR4 genome or INV104 gen-
ome (PitB).
2.3. Preparation of conjugates
Lam has been treated by reductive amination using the follow-
ing conditions: 2 mg/ml of polysaccharides were incubated for
5 days at 50 C in 300 mg/ml ammonium acetate (Sigma–Aldrich)
and 0.2 M sodium cyanoborohydride (NaBH3CN) (Sigma–Aldrich)
pH 7.5. Aminated Lam was purified by diafiltration on regenerated
cellulose membrane (cut-off 1 kDa; Millipore) and the number of
primary amino groups introduced were determined by colorimet-
ric assay [32].
The amino-oligosaccharides were vacuum dried, solubilized in
1:9 H2O:DMSO solution to a final amino group concentration of40 lmol/ml, and reacted with a 12-fold molar excess of adipic acid
bis(N-hydroxysuccinimmide) (SIDEA), in presence of 5-fold molar
excess triethylamine as compared with amino groups [33]. The
reaction was kept under gentle stirring at room temperature for
2 h. The activated oligosaccharides were obtained by precipitation
with 4 volumes of acetone and dried under vacuum. The content of
N-hydroxysuccinimide ester groups introduced was determined
[34].
Lam conjugates have been prepared in 10–100 mMNaH2PO4 pH
7 or in phosphate buffer saline pH 7 (PBS, 150 mM NaCl, 10 mM
Na2HPO4, 2 mM KCl, 2 mM KH2PO4) depending on the protein buf-
fer, using an active ester (AE):protein molar ratio of 30:1, and a
protein concentration in the range of 0.4–6 mg/ml. Reactions were
carried out overnight at room temperature with gentle stirring.
The conjugates have been purified by affinity chromatography
with His MultiTrap 96-Well Filter Plates (GE Healthcare) using
the His tag portion on the recombinant protein to bind the conju-
gate to the resin. Conjugates have been loaded on the resin (250 lg
of protein per well in a volume of 200 ll in the same buffer of con-
jugation) and incubated for 30 min after gently mixing on the well.
After, the flow through have been taken by using the vacuum air
and two washes of the resin have been done with 200 ll of PBS
buffer pH 7.2. Conjugates have been eluted from the resin by add-
ing 150 ll of elution buffer 0.5 M NaCl, 0.5 M NaH2PO4, 0.5 M Imi-
dazole pH 6.3, incubating for 15 min and collecting the flow
through; the elution has been repeated two times. Eluted conju-
gates have been dialyzed with 6–8 kDa membrane (Spectra/Por 1,
diameter 6.4 mm) against PBS buffer pH 7.2 to eliminate the elu-
tion buffer, dialysis have been carried out one day at 4 C changing
the buffer for four times. Non His-tag protein conjugates were
purified by Ultrafiltration with Vivaspin 10 K (Sartorius).
SIDEA-activated Men A, C, W, and Y oligosaccharides and their
CRM197 conjugates were obtained from GSK Vaccine Manufactur-
ing, produced as previously described [35]. Spr96/2021–Men A,
C, W, Y conjugations were carried out in 10–100 mM NaH2PO4
pH 7 or in PBS pH 7 depending on the protein buffer, at a protein
concentration of 3–3.5 mg/ml and a saccharide to protein molar
ratio of 12:1. Reactions were let to proceed overnight at room tem-
perature with gentle stirring. Purification has been done by gel fil-
tration or by ultrafiltration as reported above. The same conditions
were applied to obtain the conjugates between Men C activated
oligosaccharides and the proteins Upec-5211, Orf3526, GNA2091-
fHbp, RrgB I-II-III, spr907 and spr1418.
Men X polysaccharide was size reduced and activated for the
conjugation as reported before [36]. Conjugation of spr96/2021
was performed at a protein concentration of 10 mg/ml with an oxi-
dized polysaccharide to protein ratio 4:1 (w:w) and a saccharide to
NaBH3CN ratio of 1:1 (w:w), at 37 C for 48 h. The conjugate was
purified by ammonium sulfate precipitation (500 g/l) and the pel-
let was dissolved in 10 mM NaH2PO4 at pH 7.2. CRM197–Men X
conjugate was prepared as previously published [36].
Conjugates were characterized by micro BCA for total protein
content [37] and by HPAEC-PAD analysis (SI) for total saccharide
content.
2.4. Mice immunization
Groups of 6–8 mice (BALB/c or CD1) were immunized subcuta-
neously on days 1, 14 and 28; bleedings were performed on day 0
(pre immune), day 27 (post 2) and day 42 (post 3).
All vaccines were administered on saccharide base in a volume
of 200 ll. Lam conjugates were tested at 5 lg dose, meningococcal
conjugates at 2 lg for Men A and 1 lg for Men C, W, Y, X.
Lam and Men A, C, W, Y conjugates were tested without any
adjuvant while Men X conjugates were formulated with AlPO4 at
0.12 mg Al3+/dose.
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Animal experimental guidelines set forth by the Animal Welfare
Body of the Animal Resource Centre of our Company have been fol-
lowed for conducting all animal studies.
2.5. Analysis of antibody response by ELISA
2.5.1. Antibody response induced by the glycoconjugates against the
homologous polysaccharide
The antibody response induced by the glycoconjugates against
the homologous polysaccharide has been measured by ELISA.
Plates have been coated with the different meningococcal polysac-
charides by adding 100 ll/well of a 5 lg/ml polysaccharide solu-
tion in PBS buffer at pH 8.2 followed by incubation overnight at
4 C. Lam coating has been done at 50 lg/ml of polysaccharide
solution in 0.05 M Na2CO3–NaHCO3 buffer at pH 9.6. Coating solu-
tions were removed from the plates by washing three times with
PBS buffer with 0.05% v/v of Tween 20 (Sigma) (TPBS). A blocking
step has been then performed by adding 100 ll/well of BSA solu-
tion at 3% w/v in TPBS and incubating the plates 1 h at 37 C. Block-
ing solution has been removed from the plates by washing three
times with TPBS. 200 ll/well of pre-diluted serum (1:25 for pre
immune (negative control), 1:100–1:200 for a reference serum
and from 1:50 to 1:500 for test sera) was added in the first well
of each column of the plate, while on the other wells 100 ll of TPBS
has been dispensed. Eight two-fold serial dilutions along each col-
umn were then performed by transferring from well to well 100 ll
of sera solutions. After primary antibody dilution, plates have been
incubated for 2 h at 37 C. After three washes with TPBS, 100 ll/
well TPBS solutions of secondary antibody alkaline phosphates
conjugates (anti mouse IgG 1:10,000, Sigma–Aldrich) were added
and the plates incubated 1 h at 37 C. After three more washes with
TPBS, 100 ll/well of a 1 mg/ml of p-NPP (Sigma) in a 0.5 M di-
ethanolammine buffer pH 9.6 was added. After 30 min of incuba-
tion at room temperature, plates were read at 405 nm using a Bio-
rad plate reader. Raw data acquisition was performed by
Microplate Manager Software (Biorad). Sera titers were expressed
as the reciprocal of sera dilution corresponding to a cut-off
OD = 1 or to a cut-off OD = 0.2 depending on the study. Each immu-
nization group has been represented as the geometrical mean
(GMT) with 95% CI of the single mouse titers. The statistical and
graphical analysis has been done by GraphPad Prism 6.0 software.
2.5.2. Antibody response against the carrier proteins
The antibody response induced by the glycoconjugates against
the protein has been measured by ELISA. Plates were coated with
the different proteins at 2 lg/ml in PBS buffer at pH 7.2. Pools of
sera were tested applying the same procedure described in
Section 2.5.1.
2.5.3. Serum bactericidal assay (rSBA)
Functional antibodies induced by vaccine immunization
were analyzed by measuring the complement-mediated lysis of
N. meningitidis with an in vitro bactericidal assay [38].
A commercial lot of baby rabbit complement was used as source
of active complement. Briefly, N. meningitidis strains were grown
overnight on chocolate agar plates at 37 C in 5% CO2. Colonies
were inoculated in Mueller–Hinton broth, containing 0.25% glu-
cose to reach an OD600 of 0.05–0.08 and incubated at 37 C with
shaking. When bacterial suspensions reached OD600 of 0.25–
0.27, bacteria were diluted in the assay buffer (Gey’s balanced salt
solution with 1% BSA) at the working dilution (ca. 104 CFU/ml). The
total volume in each well was 50 ll with 25 ll of serial two-fold
dilutions of the test serum, 12.5 ll of bacteria at the working dilu-
tion and 12.5 ll of baby rabbit complement. The tested sera were
pooled and heat-inactivated for 30 min at 56 C. Negative controlsincluded bacteria incubated, separately, with the complement
serum without the test serum and with test sera and the heat-
inactivated complement. Immediately after the addition of the
baby rabbit complement, negative controls were plated on Muel-
ler–Hinton agar plates, using the tilt method (time 0). The microti-
ter plate was incubated for 1 h at 37 C, then each sample was
spotted in duplicate on Mueller–Hinton agar plates while the con-
trols were plated using the tilt method (time 1). Agar plates were
incubated overnight at 37 C and the colonies corresponding to
time 0 and time 1 (surviving bacteria) were counted. The serum
bactericidal titer was defined as the serum dilution resulting in
50% decrease in colony forming units (CFU) per ml, after 60 min
incubation of bacteria in the reaction mixture, compared to control
CFU per ml at time 0. Typically, bacteria incubated without the test
serum in the presence of complement (negative control) showed a
150–200% increase in CFU/ml, during the 60 min incubation time.
The reference strains for each meningococcal serotype used were:
F8238 (Men A); C11 (Men C); 240070 (Men W); 860800 (Men Y);
Z9615 (Men X). Men A, C, W and Y strains are O-acetyl positive.
2.6. MHC II binding prediction
Investigation on MHC II high affinity binding peptides on the
proteins has been done by IEDB Analysis Resource [39], as reported
in SI.
3. Results
3.1. Screening of potential new carrier proteins using Lam as
carbohydrate pilot model
A panel of twenty-eight proteins derived from different patho-
gens and expressed recombinantly in E. coli, was conjugated to
the neutral sugar Laminarin (Lam), a b-(1, 3) glucan with sporadic
b-(1, 6) branches, that has been studied as vaccine candidate
against C. albicans infections [31,40,41].
The proteins (Table 1 SI) were selected using the following cri-
teria: not expected toxicity based on available information, solubil-
ity in physiological buffers at concentrations of 0.4–6 mg/ml, and
presence of a sufficient number of lysines for conjugation. In addi-
tion we have in general preferred proteins with molecular weight
between 40 and 100 kDa. Lam was derivatized, at its end reducing
group, with the linker succinimido diester of adipic acid (SIDEA) in
such a way to have a terminal succinimido ester group available to
react with the lysine residues of the proteins. The activated
oligosaccharide was then reacted with the different proteins using
the same active ester/protein molar ratio (Scheme 1). A CRM197–
Lam conjugate was prepared to be used as a control in each
immunogenicity study.
In sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–Page) the glycoconjugates appeared with a typical smear,
due to the variable number of sugar chains bound to the protein
and to the polydispersion of the sugar chain length; an example
is reported in Fig. 1 SI.
The average glycosylation degree of the different glycoconju-
gates, calculated as saccharide to protein w/w ratio, varied from
1.7 to 0.1 w/w and an example is reported in Table 1. This diversity
did not correlate with the proportion of lysines on each protein and
might be due to their different reactivity depending on local
environment.
The conjugates were tested in mice without using any adjuvant
in order to highlight the intrinsic value of the carrier only. In each
immunogenicity study a control group of mice was immunized
with CRM197–Lam. Only the conjugate with spr96/2021 induced
an anti-Lam antibody titer significantly higher than the one
induced by CRM197–Lam (p = 0.01; Fig. 1). As determined by ELISA
Scheme 1. Different chemical approaches applied to obtain activated oligosaccharides or polysaccharide to be covalently coupled to the carrier protein. End terminal
reducing chemistry was applied to Lam, Men A, C, W, Y and random oxidation chemistry to Men X polysaccharide activation.
Table 1
Lam and Men C glycoconjugates characterization by saccharide to protein ratio in
term of weight/weight (w/w) and relative % of lysine residues on the carrier protein.
Carrier
protein
Lam conjugates
Saccharide/protein
(w/w)
Men C conjugates
Saccharide/protein
(w/w)
% of lysines in
the carrier
molecule
Upec-5211 0.4 0.3 7.49
Orf3526 0.3 0.1 6.05
GNA2091-fHbp 0.4 0.5 6.91
RrgB I-II-III 0.1 0.1 9.38
Spr907 0.2 0.1 7.38
Spr96/2021 0.5 0.3 5.04
Spr1418 1.2 0.6 7.33
Spr1875 0.4 0.3 4.20
CRM197 0.7 0.6 7.28
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spr96/2021 conjugate was able to induce also anti-carrier IgG,
interesting information considering the potential of spr96/2021
as antigen against S. pneumoniae (Fig. 2 SI). In Fig. 3 SI we have
reported the immunogenicity of all the Lam conjugates expressed
as the difference between the median of each group and the med-
ian of the relative control group CRM197–Lam. The small number of
mice in each group and the variability in the immunological
response, probably due to the absence of adjuvant in the formula-
tions, limited the ability to highlight statistical significant differ-
ences between several carrier proteins and their control. Since
spr96/2021 is a recombinant fusion of the two pneumococcal pro-
teins spr0096 (LysM domain secreted protein) and spr2021
(secreted PcsB protein) [42–44], we addressed the question
whether one of the two moieties could be responsible for this
strong carrier effect and we tested in mice Lam conjugates with
spr0096 and spr2021 respectively. Surprisingly no response was
induced by the spr0096 conjugate and very low by the spr2021
one (Fig. 4 SI), indicating that some feature derived from the fusion
of the two proteins is critical for the carrier activity.
3.2. Evaluation of selected proteins as carrier for serogroup C
meningococcal oligosaccharide
We then decided to test in mice the protein spr96/2021 as car-
rier for meningococcal serogroup C (Men C) oligosaccharides. We
also included in the evaluation other seven proteins, among thoseinitially tested in the Lam model, whose median of the anti Lam
response was similar, intermediate or low when compared to their
CRM197–Lam control: Orf3526 and spr907, Upec-5211 and
spr1418, GNA2091-fHbp [45], RrgB I-II-III, and spr1875. The
conjugation to Men C oligosaccharides was carried out using the
same reaction scheme described above for the Lam conjugates
(Scheme 1). The activated oligosaccharides were reacted with
the different proteins as described in Methods. The purified
glycoconjugates had a saccharide to protein ratio ranging from
0.6 to 0.1 w/w (Table 1). Also in this case a CRM197–Men C
conjugate was prepared to be used as control.
The spr96/2012 conjugate induced anti Men C polysaccharide
IgG titers comparable to those developed by CRM197 conjugate
(p > 0.05). Interestingly also Upec-5211, Orf3526, and spr1875 con-
jugates response was comparable to the control (p > 0.05), while
GNA2091-fHbp, RrgB I-II-III, spr907 and spr1418 conjugates were
inferior to the control (p < 0.01) (Fig. 2).
3.3. Evaluation of spr96/2021 as carrier for serogroup A, W, Y, and X
meningococcal saccharides
Based on the attractive behavior of spr96/2021 as carrier in
both Lam and Men C models, we decided to further explore its
potential with the meningococcal serogroups A, W, Y oligosaccha-
rides (Men A, Men W, Men Y), which are currently part of licensed
vaccines [46,47], and X polysaccharide (Men X), recently identified
as a potential candidate for vaccine development [36]. The conju-
gation to the individual Men A, Men W and Men Y oligosaccharides
was carried out essentially as described above for Men C. Similarly to
what already described for CRM197, the conjugation to Men X was
achieved after size reduction of the polysaccharide to an average
polymerization degree (avDP) of about 130 followed by random oxi-
dation of the N-acetyl glucosamine phosphate primary hydroxyl
groups and coupling of the resulting aldehyde groups to lysine e-
amine groups of the protein by reductive amination (Scheme 1)
[36]. Purified conjugates were characterized by SDS–Page (Fig. 5
SI) and for their saccharide and protein content. The glycosylation
degrees were in the range between 0.7 and 0.2 w/w (Table 2). The
SDS–Page profile of spr96/2021–Men X is similar to the one reported
for CRM197–Men X [36] and is consistent with an high molecular
weight conjugate and confirmed by the SEC-HPLC analysis reported
in SI (Fig. 6 SI). This is not surprising considering that the random
conjugation chemistry used for this conjugate can generate cross
Fig. 1. Anti-Lam antibody levels induced by Lam conjugates with new candidate carrier proteins in comparison with CRM197–Lam used as positive control. Each spot
indicates a single mouse ELISA titer, the horizontal bar refers to the geometric mean of the group and the vertical bar shows the 95% CI. Non parametric Mann–Whitney test
has been used for p value calculation.
Fig. 2. Anti-Men C antibody levels induced by glycoconjugates with different carriers in comparison with the positive control CRM197. Each dot indicates a single mouse ELISA
titer, the horizontal bar is the geometric mean of the group and the vertical bar shows the statistical 95% CI. Non parametric Mann–Whitney test has been used for p value
calculation.
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ject to a modest size reduction. Also in this case control CRM197–Men
A, W, Y and X conjugates were prepared.
When tested in mice, the spr96/2021–Men A, W,Y and X based
conjugates, after three doses of vaccine, were able to induce a levelof specific anti-Men IgGs substantially comparable with that of
CRM197 conjugates (p > 0.05; p = 0.2620; Fig. 3).
The functionality of the antibodies elicited by the spr96/2021
glycoconjugates against each meningococcal bacterial strain was
comparable with that induced by CRM197 conjugates, as
Table 2
Men A, W, Y and X glycoconjugates with spr96/2021 and CRM197, characterization by
saccharide to protein ratio in term of weight/weight (w/w).
Spr96/2021
conjugates
Saccharide/
protein (w/w)
CRM197
conjugates
Saccharide/
protein (w/w)
Men A 0.3 Men A 0.4
Men W 0.7 Men W 0.7
Men Y 0.4 Men Y 0.6
Men X 0.2 Men X 0.3
Table 3
rSBA titers induced by mice iper-immune serum obtained after immunization with
CRM197–Men A, C, W, Y and X and spr96/2021–Men A, C, W, Y and X glycoconjugate
vaccines. Men A, C, W, Y sera were tested after two doses of vaccines instead Men X
after three doses.
Rabbit complement serum bactericidal activity
Conjugates CRM197 Spr96/2021
Men A 2048 4096
Men C 1024 2048
Men W 128 512
Men Y 2048 1024
Men X 256 1024
4240 M. Tontini et al. / Vaccine 34 (2016) 4235–4242determined by rabbit complement mediated bactericidal assay
(rSBA) (Table 3).3.4. MHC II binding peptides prediction
Following the indication reported on IEDB, we have chosen 1.5
percentile rank as cut-off for a comparative analysis between the
different proteins based on the number of MHC II high affinity pep-
tides. This value allows us to take in consideration only the pep-
tides with very high affinity and obtain a useful number of
peptides to compare all the proteins tested. This rank corresponds
also to the first 20 peptides with high affinity obtained for the
amino acidic sequence of CRM197 that is the protein used as bench-
mark in our studies. Based on this investigation we obtained,
among all the proteins tested, a variable number of high affinity
binder peptides, from 0 of NarE, SAG0646 and spr1287 to 68 of
SPyAD. We did not find any correlation between the carrier func-
tionality and these results.4. Discussion
Few carrier proteins have been tested so far for clinical evalua-
tion of conjugate vaccines and only five of them (DT, TT, CRM197,
OMPC and NTHi protein D) are currently used for licensed vaccines
against bacterial infections. The increased attention to multivalent
combination vaccines and the possible CIES or bystander interfer-
ence affecting polysaccharide conjugate antigens drives through
the need of alternative carrier proteins, which could also be useful
to target multiple and different virulence factors (protective epi-
topes) of pathogens. Accordingly we have conducted a screening
of several bacterial proteins to investigate their potential as carrier
for glycoconjugate vaccines and identify possible candidates for
further development. In a first screening step, twenty eight pro-
teins were conjugated to Lam using the end-groups chemistry
illustrated in Scheme 1.Fig. 3. Anti-Men A, W, Y, X antibody levels induced by spr96/2021–Men A, W, Y, X
conjugates. Each dot indicates a single mouse ELISA titer, the horizontal bar is the ge
parametric Mann–Whitney test has been used for p value calculation.The protein spr96/2021 emerged as a promising carrier induc-
ing titers significantly higher than CRM197–Lam (Fig. 1). Since
Lam is a non-charged saccharide we thought interesting to extend
the study using Men C oligosaccharides which have a negatively
charged repeating unit. Accordingly spr96/2021 and also some
other proteins of those initially tested in the Lam model and show-
ing similar, intermediate or low median anti Lam response as com-
pared to their CRM197–Lam control, were conjugated to Men C
oligosaccharides and tested in mice. Spr96/2021–Men C, induced
anti-Men C CPS IgG titers comparable to those developed by
CRM197–Men C, confirming the results obtained in the Lam model.
Subsequently the potential of spr96/2021 to work as carrier for
carbohydrate antigens was confirmed with Men A, Men W, Men
Y and Men X. The corresponding conjugates induced in mice
anti-meningococcal IgGs and rSBA titers comparable to those
developed by glycoconjugates of CRM197 which is a well-known
carrier and successfully used in several licensed glycoconjugate
vaccines like MenjugateTM, MENVEOTM and Prevenar (Wyeth).
The response induced by the Men C conjugates with the other
selected proteins did not always follow the same trend of the ini-
tial screening with Lam. In fact while Upec-5211, Orf3526 and
spr1875 conjugates induced anti-Men C CPS IgG titers comparable
to CRM197–Men C, spr907, GNA2091-fHbp, RrgB I-II-III conjugates
were significantly less immunogenic.
The role of the carrier in glycoconjugate vaccines is to provide
T-cell epitopes which bind to the class II MHC and subsequently,
on the surface of the antigen presenting cells, interact with the
CD4+ T cell receptor to trigger signals which induce B-cell differen-
tiation in carbohydrate-specific plasma and memory cells. Many
factors are important in determining the ability of a protein to
work as carrier. As well as the number of MHC II high affinity bind-
ing peptides, other factors like the glycoconjugate processing
inside the antigen presenting cells, the strength of the interactionglycoconjugates in comparison with the positive control CRM197–Men A, W, Y, X
ometric mean of the group and the vertical bar shows the statistical 95% CI. Non
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extent and localization of glycosylation, might affect the integrity
of the key T-cell epitopes, therefore determining the immuno-
genicity of the conjugate.
By applying the MHC class II prediction algorithms IEDB Analy-
sis Resource (IEDB-AR) [39] we did not find any correlation
between the number of high affinity MHC II binders in the carriers
and the immunogenicity of their corresponding Lam conjugates.
Similarly we did not find a correlation between immunogenicity
of the Lam conjugates and their glycosylation degree as well as
the carrier molecular weight.
In terms of chemical procedure we should consider that the
chemistry used in this work is based on the conjugation to the lysine
residues of the proteins. This process might have selected preferen-
tially the protein whose highest affinity T-cell epitopes do not con-
tain lysines in critical position. Moreover for a given carrier the
glycosylation profile obtained with a neutral oligosaccharide might
differ from that of charged one. It would be interesting to test conju-
gation chemistries that involve different amino acid residues and to
analyze the glycosylation profiles of carriers conjugated to charged
and non-charged saccharides, as well as the anti-carrier antibodies
induced by the different conjugates.
Interestingly when the non-fusion proteins spr0096 or spr2021
were tested as Lam conjugates, no response or significantly lower
than CRM197 response was induced respectively by spr0096 and
spr2021. This behavior could be due to several factors including
the different molecular weights (18.7 kDa for spr0096 and
38.9 kDa for spr2021) and the number and affinity of MHC class
II binding peptides. Moreover the glycosylation profile of the fusion
protein could be different for the fusion and single proteins, lead-
ing to a different impact on the preservation of T-cell epitopes
and/or the conjugates processing inside the antigen presenting
cells; we are currently investigating this aspect.
In conclusion, by screening a large number of recombinant pro-
teins and focusing on two types of saccharide structures, the b-
glucan based non charged Laminarin and the polyanionic meningo-
coccal oligosaccharides, we have identified, based on immunolog-
ical data, a panel of proteins that deserve further attention. In
particular spr96/2021 is a new potential protein carrier for carbo-
hydrate haptens which might also offer pathogen-protective effect.
We are accumulating evidences that spr96/2021 can be success-
fully used as carrier for pneumococcal derived carbohydrates and
in meningococcal multivalent formulations, this aspect has not
been addressed in this paper and will be part of a comprehensive
preclinical investigation. For a new vaccine, including conjugate
vaccines, time to market is variable. While in the 1980s it was
determined more by the discovery phase, impressive technological
revolutions made the discovery phase significantly shorter, but at
the same time the development path which includes process
development, clinical and regulatory development, and GMP man-
ufacturing is longer and fully justified by increased cGMP and good
clinical practice standards, making the overall time to market still
in the range of 10–15 years [48].Conflict of interests
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